FOR IMMEDIATE RELEASE

November 19, 2013

AnGes MG, Inc.

Vical Announces Results of a Phase 3 Trial of Allovectin® at the International Meeting of the Society for Melanoma Research

AnGes MG, Inc. ("AnGes") announced that its development partner, Vical, Inc. ("Vical") presented detailed results of a Phase 3 trial of Allovectin® on November 18, 2013, at the 10th International Meeting of the Society for Melanoma Research (Philadelphia, PA).

Vical announced the detailed data to the public for the first time since it announced that the trial failed to demonstrate a statistically significant improvement for either the primary endpoint of objective response rate or the secondary endpoint of overall survival on August 12, 2013.

According to the results presented by Vical, the primary endpoint of objective response rate (complete response and partial response rate after 24 weeks from the first injection) was 4.6% (12 in 260) in the Allovectin® group, compared with 12.3% (16 in 130) in the control arm (first-line chemotherapy).

The trial also failed to demonstrate a statistically significant improvement in the secondary endpoint of median overall survival, with a median overall survival of 18.6 months in Allovectin® group and 24.1 months in the control arm.

The duration of response and overall survival of responders alone tended to be longer with Allovectin® than with chemotherapy. For example, survival of 83% of responders (10 in 12) with Allovectin® was observed at 6.5 years from the trial start or 3.5 years from the last-patient-out. Six of those responders with Allovectin® survived more than 4.5 years, and the longest, for 6 years. In comparison, the survival rate of chemotherapy responders was 30% and only 1 patient survived longer than 4.5 years. This indicates that Allovectin® may be only effective in a portion of patients with metastatic melanoma; however, it may have strong efficacy in responders.

A copy of the presentation is available on Vical's website.
http://www.vical.com/investors/events-presentations/Event-Details/2013/Allovectin-Phase-3-Results---Society-for-Melanoma-Research-Meeting/default.aspx

AnGes has been examining the detailed data obtained from the Phase 3 trial. AnGes will review the application of Allovectin® to cancers other than melanoma, such as head and neck cancer, and take future measures.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

AnGes MG, Inc.
Corporate Communications
TEL: +81-3-5730-2641, FAX: +81-3-5730-2635
http://www.anges-mg.com
Email:info@anges-mg.com